Research programme: WRN inhibitors - Nimbus Therapeutics
Alternative Names: Werner syndrome helicase inhibitors - Nimbus TherapeuticsLatest Information Update: 11 Jan 2024
At a glance
- Originator Nimbus Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Werner syndrome helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer